UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.)

 \boxtimes

Filed by the Registrant

Reg	d by a Party other than the istrant ck the appropriate box:
	Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under §240.14a-12
	MoonLake Immunotherapeutics
	(Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement if other than the Registrant)
	Payment of Filing Fee (Check all boxes that apply):
\boxtimes	No fee required.
	Fee paid previously with preliminary materials.
	Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.



MOONLAKE IMMUNOTHERAPEUTICS

2024 Annual General Meeting of Shareholders Vote by June 4, 2024 11:59 PM ET

MOONLAKE IMMUNOTHERAPEUTICS DORFSTRASSE 29 ZUG, 9WITZERLAND 6300



V42712-P10410

You invested in MOONLAKE IMMUNOTHERAPEUTICS and it's time to vote!

You have the right to vote on proposals being presented at the Annual General Meeting of Shareholders. This is an important notice regarding the availability of proxy materials for the shareholder meeting to be held on June 5, 2024.

Get informed before you vote

View the Notice, Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 22, 2024. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.



For complete information and to vote, visit www.ProxyVote.com

Control#



Vote in Person at the Meeting*

June 5, 2024 8:00 a.m. Eastern Time

At the offices of Gibson, Dunn & Crutcher LLP Located at 200 Park Avenue New York, New York 10166

Smartphone users

Point your camera here and vote without entering a control number



^{*}Please check the meeting materials for any special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares.

THIS IS NOT A VOTABLE BALLOT

This is an overview of the more complete proxy materials that are available to you on the Internet. You may view the proxy materials at www.ProxyVote.com or easily request a paper copy. We encourage you to access and review all of the important information contained in the proxy materials before voting. Please follow the instructions on the reverse side to vote on these important matters.

Voting Items R			
1.	Election of the two Class II director nominees to serve until the 2027 Annual General Meeting of Shareholders and until their successors are duly elected and qualified.		
	Nominees:	⊘ For	
	01) Catherine Moukheibir 02) Dr. Ramnik Xavier		
2.	Ratification, by ordinary resolution, of the selection of Baker Tilly US, LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024.	⊘ For	
3.	Approval of, on an advisory basis, the compensation of the Company's named executive officers.	For	
4.	Non-binding advisory vote on the frequency of future advisory votes on executive compensation.	1 Year	
NOTE: Such other business as may properly come before the meeting or any adjournment or postponement thereof.			

V42713-P10410

Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click "Delivery Settings".